Christopher H. So
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christopher H. So has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Philip D. Tran
Roseman University of Health Sciences, School of Pharmacy, Henderson, NV 89014, USA
2 shared publicationsSelina Crivello
Roseman University of Health Sciences School of Pharmacy, Henderson, USA
2 shared publicationsStacy A. Henry
Roseman University of Health Sciences School of Pharmacy, Henderson, USA
2 shared publicationsTajinder Badial
Touro University Nevada, Henderson, USA
2 shared publicationsAlec Z. Jacinto
Roseman University of Health Sciences School of Pharmacy, 11 Sunset Way, Henderson, NV, 89014, USA
1 shared publication- Alec Z. Jacinto
Roseman University of Health Sciences, School of Pharmacy, Henderson, NV 89014, USA
1 shared publication
Latest Publications
- 1 August 2021
- Published by Canadian Science Publishing in Biochemistry and Cell Biology
- Vol. 99 (4) , 508-518
G protein coupled receptor kinase 5 modifies the nucleolar stress response activated by actinomycin D
G protein coupled receptor kinase 5 (GRK5) is localized within the nucleus and moderates functions such as DNA transcription, in addition to its localization at the plasma membrane. In this report, we show that GRK5 modifies the nucleolar stress response activated by the DNA polymerase inhibitor, actinomycin D (ActD). We show an increased sensitivity to the apoptotic effects of ActD on cervical HeLa cells and the breast cancer cell line MDA MB 231 with reduced protein expression of GRK5. We also tested two types of breast cancer cells (MDA MB 231 and MCF7 cells) and found that the rate of response to ActD varied between them because they have innate differences in the protein expression of GRK5. We also found that GRK5 phosphorylates nucleophosmin (NPM1) at T199 before and during the early stages of ActD treatment. Phosphorylation at T199 increases the ability of NPM1 to interact with p14ARF in vitro, which may affect the protein expression levels of p14ARF. We found that the expression levels of p14ARF were lower in the cells transfected with the control shRNA, but higher in cells transfected with GRK5 shRNA. Collectively, this suggests that GRK5 modifies the nucleolar stress response associated with ActD.
- 1 August 2021
- Published by Canadian Science Publishing in Biochemistry and Cell Biology
- Vol. 99 (4) , 508-518
G protein coupled receptor kinase 5 modifies the nucleolar stress response activated by actinomycin D
G protein coupled receptor kinase 5 (GRK5) is localized within the nucleus and moderates functions such as DNA transcription, in addition to its localization at the plasma membrane. In this report, we show that GRK5 modifies the nucleolar stress response activated by the DNA polymerase inhibitor, actinomycin D (ActD). We show an increased sensitivity to the apoptotic effects of ActD on cervical HeLa cells and the breast cancer cell line MDA MB 231 with reduced protein expression of GRK5. We also tested two types of breast cancer cells (MDA MB 231 and MCF7 cells) and found that the rate of response to ActD varied between them because they have innate differences in the protein expression of GRK5. We also found that GRK5 phosphorylates nucleophosmin (NPM1) at T199 before and during the early stages of ActD treatment. Phosphorylation at T199 increases the ability of NPM1 to interact with p14ARF in vitro, which may affect the protein expression levels of p14ARF. We found that the expression levels of p14ARF were lower in the cells transfected with the control shRNA, but higher in cells transfected with GRK5 shRNA. Collectively, this suggests that GRK5 modifies the nucleolar stress response associated with ActD.
- 4 January 2021
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 476 (3) , 1505-1516
G protein-coupled receptor kinase 2 modifies the cellular reaction to cisplatin through interactions with NADPH oxidase 4
G protein-coupled receptor kinases (GRKs), in addition to their role in modulating signal transduction mechanisms associated with activated G protein-coupled receptors (GPCRs), can also interact with many non-GPCR proteins to mediate cellular responses to chemotherapeutics. The rationale for this study is based on the presumption that GRK2 modulates the responses of cancer cells to the chemotherapeutic cisplatin. In this report, we show that GRK2 modulates the responses of cancer cells to cisplatin. Cervical cancer HeLa cells stably transfected with GRK2 shRNA, to decrease GRK2 protein expression, show increased sensitivity to cisplatin. Of interest, these cells also show increased accumulation of NADPH, associating with decreased NADP buildup, at low concentrations of cisplatin tested. These changes in NADPH and NADP levels are also observed in the breast cancer MDA MB 231 cells, which has lower endogenous GRK2 protein expression levels, but not BT549, a breast cancer cell line with higher GRK2 protein expression. This effect of NADPH accumulation may be associated with a decrease in NADPH oxidase 4 (NOX4) protein expression, which is found to correlate with GRK2 protein expression in cancer cells—a relationship which mimics that observed in cardiomyocytes. Furthermore, like in cardiomyocytes, GRK2 and NOX4 interact to form complexes in cancer cells. Collectively, these results suggest that GRK2 interacts with NOX4 to modify cisplatin sensitivity in cancer cells and may also factor into the success of cisplatin-based regimens.
- 4 January 2021
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 476 (3) , 1505-1516
G protein-coupled receptor kinase 2 modifies the cellular reaction to cisplatin through interactions with NADPH oxidase 4
G protein-coupled receptor kinases (GRKs), in addition to their role in modulating signal transduction mechanisms associated with activated G protein-coupled receptors (GPCRs), can also interact with many non-GPCR proteins to mediate cellular responses to chemotherapeutics. The rationale for this study is based on the presumption that GRK2 modulates the responses of cancer cells to the chemotherapeutic cisplatin. In this report, we show that GRK2 modulates the responses of cancer cells to cisplatin. Cervical cancer HeLa cells stably transfected with GRK2 shRNA, to decrease GRK2 protein expression, show increased sensitivity to cisplatin. Of interest, these cells also show increased accumulation of NADPH, associating with decreased NADP buildup, at low concentrations of cisplatin tested. These changes in NADPH and NADP levels are also observed in the breast cancer MDA MB 231 cells, which has lower endogenous GRK2 protein expression levels, but not BT549, a breast cancer cell line with higher GRK2 protein expression. This effect of NADPH accumulation may be associated with a decrease in NADPH oxidase 4 (NOX4) protein expression, which is found to correlate with GRK2 protein expression in cancer cells—a relationship which mimics that observed in cardiomyocytes. Furthermore, like in cardiomyocytes, GRK2 and NOX4 interact to form complexes in cancer cells. Collectively, these results suggest that GRK2 interacts with NOX4 to modify cisplatin sensitivity in cancer cells and may also factor into the success of cisplatin-based regimens.
- Open Access
- 16 October 2020
- Published by Elsevier in Cell Stress and Chaperones
- Vol. 26 (1) , 187-197
G protein–coupled receptor kinase 2 modifies the ability of Caenorhabditis elegans to survive oxidative stress
- 16 October 2020
- Published by Elsevier in Cell Stress and Chaperones
- Vol. 26 (1) , 187-197
Open AccessG protein–coupled receptor kinase 2 modifies the ability of Caenorhabditis elegans to survive oxidative stress
- 5 August 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 530 (4) , 692-698
G protein coupled receptor kinases modulate Caenorhabditis elegans reactions to heat stresses
- 5 August 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 530 (4) , 692-698
G protein coupled receptor kinases modulate Caenorhabditis elegans reactions to heat stresses
- 30 July 2019
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 461 (1-2) , 103-118
G protein-coupled receptor kinase 5 modifies cancer cell resistance to paclitaxel
G protein-coupled receptor kinases (GRKs) phosphorylate the activated forms of G protein-coupled receptors (GPCRs), leading to receptor desensitization and internalization. In addition, GRKs can modify the activity of many non-GPCR-signaling pathways as well, controlling other cellular functions beyond that directly associated with a GPCR. In this report, we show that cervical cancer HeLa cells and breast cancer MDA MB 231 cells with reduced GRK5 expression display increased sensitivity to the apoptotic effects of paclitaxel (Taxol). This effect in cancer cells with low GRK5 levels could be because of blunted histone deacetylase 6 (HDAC6) activity that leads to an increase in α-tubulin acetylation levels, which augments paclitaxel sensitivity. We demonstrate that GRK5 and HDAC6 form a signaling complex in cells and in vitro. GRK5 phosphorylates HDAC6 at Ser-21 to promote its deacetylase activity. Therefore, the GRK5–HDAC6 interaction may contribute to paclitaxel resistance in cancer cells.
- 30 July 2019
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 461 (1-2) , 103-118
G protein-coupled receptor kinase 5 modifies cancer cell resistance to paclitaxel
G protein-coupled receptor kinases (GRKs) phosphorylate the activated forms of G protein-coupled receptors (GPCRs), leading to receptor desensitization and internalization. In addition, GRKs can modify the activity of many non-GPCR-signaling pathways as well, controlling other cellular functions beyond that directly associated with a GPCR. In this report, we show that cervical cancer HeLa cells and breast cancer MDA MB 231 cells with reduced GRK5 expression display increased sensitivity to the apoptotic effects of paclitaxel (Taxol). This effect in cancer cells with low GRK5 levels could be because of blunted histone deacetylase 6 (HDAC6) activity that leads to an increase in α-tubulin acetylation levels, which augments paclitaxel sensitivity. We demonstrate that GRK5 and HDAC6 form a signaling complex in cells and in vitro. GRK5 phosphorylates HDAC6 at Ser-21 to promote its deacetylase activity. Therefore, the GRK5–HDAC6 interaction may contribute to paclitaxel resistance in cancer cells.